Listar por autoría "880ddd7d-49b7-4d93-a974-e6dc12ddfa28"

Mostrando ítems 1-4 de 4

    • openAccess   Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design 

      Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar, Luis; López‐Lereu, Maria Pilar; Monmeneu, Jose V.; Amiguet, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; De la Espriella, Rafael; Sanchis, Juan; Chorro, Francisco J.; Bayes-Genis, Antoni; Núñez, Julio; Myocardial‐IRON Investigators Wiley (2018)
      Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for ...

    • closedAccess   Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction 

      Palau, Patricia; Domínguez Mafé, Eloy; Seller, Julia; Sastre, Clara; Sanchis, Juan; López, Laura; Bodí, Vicent; Llàcer, Pau; Miñana, Gema; De la Espriella, Rafael; Bayes-Genis, Antoni; Núñez, Julio Elsevier (2022)
      Introduction and objectives: Little is known about the usefulness of heart rate (HR) response to exercise for risk stratification in heart failure with preserved ejection fraction (HFpEF). Therefore, this study aimed ...

    • closedAccess   Iron deficiency and short-term adverse events in patients with decompensated heart failure 

      Palau, Patricia; Llàcer, Pau; Domínguez Mafé, Eloy; Tormo, Juan Pablo; Zakarne, Rim; Mollar, Anna; Martínez, Ana; Miñana, Gema; Santas, Enrique; Almenar-Bonet, Luis; Fácila, Lorenzo; De la Espriella, Rafael; Núñez, Eduardo; Manzano, Luis; Bayes-Genis, Antoni; Núñez, Julio Springer (2021-03-15)
      Background: For patients with heart failure (HF), iron deficiency (ID) is a common therapeutic target. However, little is known about the utility of transferrin saturation (TSAT) or serum ferritin for risk stratification ...

    • openAccess   Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial 

      Núñez, Julio; Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar-Bonet, Luis; Lopez-Lereu, Maria Pilar; Monmeneu Menadas, Jose Vicente; Amiguet Comins, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; De la Espriella, Rafael; Lupón, Josep; Navarro, Jorge; Górriz, José Luis; Sanchis, Juan American Heart Association (2020-02-13)
      Background Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The ...